Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's enterprise value to sales, at 3.86 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Most analysts recommend that the stock should be sold or reduced.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.45B
BBB
1T
A
613B
BBB
433B
AA
-
350B
AA
292B
AAA
239B
A
206B
A
204B
A
163B
AA
Average 350.39B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. ROVI Stock
  5. Ratings Laboratorios Farmaceuticos Rovi, S.A.